Endorphins and Opiate Antagonists in Psychiatric Research: Clinical ImplicationsSpringer Science & Business Media, 2012 M12 6 - 510 páginas The discovery of new molecules that function in neuronal communication can be viewed as a progression of steps beginning with the identification of the molecular structure, moving to the understanding of the mecha nisms mediating the synaptic action, and to the appraisal of the involve ment of the new molecules in various neuronal mechanisms, and finally reaching the evaluation of this molecule's role in brain function and the consequences that are triggered by its abnormalities. Enkephalins have followed such a pattern, and the present publication expresses the salient points of the last two phases in this succession. Enkephalins were discovered in December 1975; in addition to pain threshold regulation, their participation in other brain functions was soon ascertained. Perhaps, there are multiple recognition sites for multiple molecular forms of endogenous enkephalins; similarly to other transmitter recognition sites, these are coupled with ionic and nucleotide amplifying systems; thus, when activated, they can modify membrane funtion and ionic permeability of membranes. The present publication probes the current status of our knowledge concerning the consequences related to abnormalities in enkephalin storage, release, and synthesis. However, since our basic understanding of enkephalins is incomplete, the views reported should be considered to be in a state of flux. |
Dentro del libro
Resultados 1-5 de 82
Página 8
... concentrations of uncharacterized endorphins in the CSF of manic ( Lindström et al . , 1978 ) as well as depressed ( Terenius et al . , 1977 ) patients . Administration of naloxone in low doses ( s.c. ) produced no beneficial effects in ...
... concentrations of uncharacterized endorphins in the CSF of manic ( Lindström et al . , 1978 ) as well as depressed ( Terenius et al . , 1977 ) patients . Administration of naloxone in low doses ( s.c. ) produced no beneficial effects in ...
Página 17
... concentrations of radioactive ligand , and ( 2 ) the rapid washing with cold buffer of filters after the bound homogenate was filtered or of pellets of bound homogenate following centrifugation . This second modification reduced ...
... concentrations of radioactive ligand , and ( 2 ) the rapid washing with cold buffer of filters after the bound homogenate was filtered or of pellets of bound homogenate following centrifugation . This second modification reduced ...
Página 18
... concentrations of up to 150 mM enhance antagonist and depress agonist binding . This discriminatory effect of sodium will be discussed later in this review . The suggestion that protein is involved in the opiate binding site is ...
... concentrations of up to 150 mM enhance antagonist and depress agonist binding . This discriminatory effect of sodium will be discussed later in this review . The suggestion that protein is involved in the opiate binding site is ...
Página 20
... ( concentration able to displace the binding of 50 % of the labeled drug ) since both competitor and labeled antagonist have similar shifts in affinity in the presence of sodium . However , the ED50 of agonists , in the presence of sodium ...
... ( concentration able to displace the binding of 50 % of the labeled drug ) since both competitor and labeled antagonist have similar shifts in affinity in the presence of sodium . However , the ED50 of agonists , in the presence of sodium ...
Página 21
... concentration of 10-6 M ( Crain et al . , 1977 ) . The potencies of opiate agonists in this sys- tem correlate well ... concentrations of naloxone ( 10-8-10-6 M ) . The electrophysiological effectiveness of opiates led us to study op ...
... concentration of 10-6 M ( Crain et al . , 1977 ) . The potencies of opiate agonists in this sys- tem correlate well ... concentrations of naloxone ( 10-8-10-6 M ) . The electrophysiological effectiveness of opiates led us to study op ...
Contenido
1 | |
4 | |
9 | |
15 | |
CHAPTER 2 | 41 |
CHAPTER 3 | 61 |
Possible Roles of Prostaglandins in Mediating Opioid Actions | 75 |
CHAPTER 5 | 89 |
CHAPTER 13 | 257 |
CHAPTER 14 | 271 |
CHAPTER 15 | 291 |
CHAPTER 16 | 305 |
CHAPTER 18 | 333 |
CHAPTER 19 | 347 |
CHAPTER 21 | 375 |
Enkephalin Naloxone and DESTYR¹yEndorphin | 399 |
CHAPTER 6 | 99 |
CHAPTER 7 | 127 |
CHAPTER 8 | 161 |
CHAPTER 9 | 179 |
CHAPTER 10 | 213 |
CHAPTER 11 | 231 |
CHAPTER 12 | 245 |
CHAPTER 23 | 407 |
CHAPTER 24 | 427 |
CHAPTER 25 | 439 |
CHAPTER 26 | 451 |
CHAPTER 27 | 459 |
Index | 477 |
Otras ediciones - Ver todas
Endorphins and Opiate Antagonists in Psychiatric Research: Clinical Implications Nandkumar S. Shah,Alexander G. Donald Sin vista previa disponible - 2012 |
Términos y frases comunes
Acad acid ACTH action activity administration Akil analgesia analgesic analogs antipsychotic assay B-LPH Barchas behavioral effects Biochem Bloom Brain Res Bunney cerebrospinal fluid chronic clinical concentrations decrease depressed patients dialysate disorders dopamine doses double-blind drugs DTYE Effects of naloxone electrical stimulation endogenous opiates endogenous opioid peptides endorphin levels endorphins enkephalin fraction Goldstein Guillemin hallucinations haloperidol hemodialyses Höllt human hypothalamus immunoreactivity increase infusion inhibition injection Kastin Kline Kosterlitz Lancet ligands lipotropin manic Met-enkephalin methadone morphine naloxone naltrexone narcotic antagonist Natl Nature London neuroleptic neurons Neurosci normal nucleus opiate agonists opiate antagonist opiate peptides opiate receptors opioid peptides pain periaqueductal gray Pert Pharmacol pharmacological placebo plasma potent Proc prolactin Psychiatry psychotic rat brain receptor binding release reported response role schizo schizophrenic schizophrenic patients Science serum Snyder spinal ẞ-endorphin Stereospecific striatum studies suggest symptoms syndrome Terenius tissue treatment vitro Wahlström